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Abstract
Introduction: Hepatitis C virus (HCV) infection is a serious health problem in Georgia.
Methods: We conducted a prospective study to identify and characterize the natural history of recent HCV
infection since very first days of infection. Recent HCV infection was defined as detectable plasma HCV RNA in the
absence of anti-HCV antibodies.
Results: A total of 7600 HCV seronegative blood donors and 3600 HCV seronegative drug users were screened for
recent HCV infection. Among them 7 (0.09 %) blood donors and 10 (0.28 %) drug users tested positive for HCV RNA
and were classified as having recent HCV infection. Of these 17 patients 4 (23.5 %) spontaneously cleared the virus by
the end of 24 week follow-up. Five clinical forms of recent HCV infection were identified during the follow-up. Four
patients had symptomatic disease, including 3 patients with jaundice and other clinical symptoms (2 of them cleared
virus) and 1 patient only had other symptoms without jaundice. All symptomatic patients had ALT elevation. Three
distinct variants of asymptomatic disease were identified in 13 patients: 9 patients had ALT elevation and none cleared
the virus; 2 patients developed chronic disease without ALT elevation; 2 patients cleared virus without anti-HCV
seroconversion and without ALT elevation; this form can be described as transitory HCV viremia.
Conclusion: Additional studies are needed to define clinical and public health implications of transitory HCV viremia.
Our study suggests the need for implementing nucleic acid testing of blood donors and key populations in order to
more effectively identify HCV infected persons.
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Background
An estimated 185 million people are living with hepatitis
C virus (HCV) globally and up to 500,000 deaths are at-
tributed to the disease annually [1, 2]. Approximately
25 % of cases HCV infections are self-limited resulting
in spontaneous clearance after acute infection, with the
remaining 75 % of patients progressing to chronic dis-
ease [3]. Up to one third of patients with chronic
hepatitis C develop liver cirrhosis and/or hepatocellular
carcinoma (HCC) [3–5].
Although there is no protective vaccine against HCV,
current treatment modalities offer high cure rates, which
are expected to further improve with more powerful
therapies currently in development [6]. This has brought
promise that HCV can be eliminated or more effectively
prevented through treating patients with hepatitis C, a
so called treatment as prevention strategy [7]. However,
there are serious challenges, including access to HCV
testing, care and treatment services. For example, in the
United States only half of the estimated 3.5 million
people living with HCV infection were aware of their
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status and only 16 % of them were prescribed treatment
[8]. The access is even more limited in resource-poor
countries [9]. In addition, the risk of re-infection after
successful curative therapy, which is substantial among
injection drug users (IDU), should also be taken into ac-
count [10].
Despite the tremendous progress in the field of hepa-
titis C, knowledge about the natural course of acute dis-
ease since the very early days of infection remains
limited. Acute HCV is frequently asymptomatic making
it very difficult to identify patients early in the course of
disease. Therefore, studying acute HCV infection, prior
to their seroconversion, by detecting seronegative sub-
jects who are HCV RNA seropositive is an important
method of early detection and can provide additional in-
sights into the immunology and virology of acute phase
of the infection.. From a public health standpoint, identi-
fication of factors associated with recent infection can
help to better understand drivers of transmission in
order to design preventive strategies.. Altogether im-
proved knowledge of recent HCV infection can contrib-
ute to the development of interventions that can prevent
establishment of chronic infection.
Georgia is an independent country located in Eastern
European region between Russia and Turkey. Georgia
experienced a rapid increase in the IDU population in
the 1990s, which has resulted in a high HCV prevalence
in the country [11]. Based on population-based survey
an estimated 6.7 % of the adult population of the capital
city of Tbilisi has hepatitis C, with prevalence reaching
70 % among IDUs [11, 12]. The other group found to be
at risk of HCV in Georgia were paid blood donors, [13]
who have been identified to be at high risk of blood
borne infections in other settings as well [14].
The objective of the present study was to identify and
characterize the course of recent HCV infection by iden-
tifying and prospectively studying patients who were
HCV RNA positive prior to anti-HCV seroconversion.
Methods
We conducted a 3-year prospective observational study
to identify and follow patients with recent HCV infec-
tion, defined as detectable plasma HCV RNA in the ab-
sence of anti-HCV antibodies. For this purpose we
tested anti-HCV seronegative blood donors and anti-
HCV seronegative IDUs for qualitative detection of
HCV RNA in plasma. Blood donors were initially
screened for HCV at blood banks, while IDUs received
their first HCV test at HIV testing and counseling sites.
We applied a mini-pool approach to screen for HCV
RNA by testing a pool of 6 samples. Non-reactive pools
were excluded from further investigation, while reactive
pools were further resolved by testing each individual
sample in the pool. Remaining individual blood
specimens from initial screening were used for mini-
pool testing.
Detection of HCV RNA in anti-HCV negative persons
gave us the unique possibility to identify early HCV in-
fection in the seronegative window period (before sero-
conversion) and to follow the natural course of disease.
All HCV RNA positive persons underwent additional
investigations, including plasma HCV RNA quantifica-
tion (viral load), HCV genotyping, ALT level determin-
ation and clinicalimitatl examination immediately after
identification their recent HCV infection. Patients were
followed for 6 months and anti-HCV, viral load, ALT,
bilirubin and clinical/physical examinations were re-
peated at 2, 4, 8, 12 and 24 weeks of follow-up.
Because of the risk of co-infections with HIV or HBV
all patients with recent HCV infection were tested for
infection with these viruses. However, none of them had
either infection.
Spontaneous HCV clearance was defined as two con-
secutive negative HCV RNA results after a confirmed re-
cent HCV infection. The time point when spontaneous
viral clearance occurred was defined as the midpoint be-
tween the date of the last detectable measurement of
HCV RNA and the date of the first of two consecutive
samples with undetectable HCV RNA. The time point
when anti-HCV seroconversion occurred was defined as
the midpoint between the date of the last negative and
the first positive anti-HCV test. ALT elevation was de-
fined as a level of >40 U/l,
All patients with recent infection were interviewed to
collect demographic and epidemiological information.
The probable mode of HCV transmission was assigned
based on the reported risk factors by applying the pre-
sumed hierarchical order of probability of acquiring the
infection. Percutaneous exposure, including IDU, was
considered as the strongest risk factor for acquisition.
Sexual transmission was assumed if a person reported
no risk behavior other than having sexual intercourse
with person known to be HCV positive. The mode of
transmission was classified as undetermined if a person
reported no risk factors for acquiring HCV.
Screening for HCV antibodies was conducted using
the ORTHO HCV 3.0 enzyme linked immunosorbent
assay (EIA). Qualitative detection of HCV RNA was per-
formed using COBAS AMPLICOR HCV Test, v2.0
(Roche Diagnostics, Germany) which has a lower detec-
tion limit of <50 IU/ml; viral load was measured using
COBAS TaqMan HCV 2.0 Test (Roche Diagnostics,
Germany) which has a lower detection limit of <10 IU/
ml; HCV genotype was determined using reverse
hybridization line probe assay (INNO LiPA) using VER-
SANT HCV Genotype kit 2.0 (Innogenetics, Belgium).
All laboratory assays were performed in accordance with
the manufacturer’s instructions.
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The study was approved by the institutional review
boards (IRB) of the Infectious Diseases, AIDS and Clin-
ical Immunology Research Center and Johns Hopkins
University. Informed written consent was obtained from
all persons.
Results
A total of 7600 HCV seronegative blood donors and
3600 HCV seronegative IDUs were screened for recent
HCV infection. Among them 7 (0.09 %) blood donors
and 10 (0.28 %) IDUs tested positive for HCV RNA and
were classified as having recent HCV infection.
Baseline characteristics of 17 patients with recent
HCV infection are summarized in Table 1. Briefly, the
majority was men (88.2 %) and their median age was
31 years. Twelve patients (including 2 blood donors)
were infected through IDU (70.6 %), one patient ac-
quired HCV via sexual contact (5.9 %) and the mode of
transmission could not be determined in four patients
(23.5 %). Overall, 59 % of patients were infected with an
HCV genotype 1 virus. Overall, 4 (23.5 %) patients spon-
taneously cleared the virus by the end of the 24 week
follow-up.
Five clinical forms of recent HCV infection were iden-
tified from the follow-up studies (Fig. 1).
Two variants of symptomatic disease were identified
(Fig. 1). In 3 patients the disease was clinically mani-
fested by jaundice and other clinical symptoms; while 1
patient only had other clinical symptoms without jaun-
dice. These symptoms included fatigue, malaise, nausea,
fever and arthralgia. Symptoms occurred after 4–8 weeks
of follow-up. All 4 symptomatic patients had elevated
levels of ALT, with median peak value of 1218 IU/l
(range: 410–2050). Bilirubin was elevated in all 4 pa-
tients, ranging between 3.6 and 8.0 mg/dl at peak levels
in patients with jaundice, and reaching 1.8 mg/dl in pa-
tient with other clinical symptoms only. All of these sub-
jects experienced anti-HCV seroconversion after a
median of 6 weeks (range: 3–10). Of these 4 patients, 2
spontaneously cleared the virus. One patient, carrying
genotype 1b HCV, cleared the virus by week 12. In an-
other patient with genotype 2a/2c virus plasma HCV
RNA became negative at week 24.
Three distinct clinical and laboratory variants of
asymptomatic disease were identified in 13 patients
(Fig. 1). The first group consisted of 9 patients with ele-
vated levels of ALT (the peak median ALT value was
957 IU/l [range: 220–1685]). Three patients had slightly
elevated levels of bilirubin not exceeding 2 mg/dl. All of
these 9 patients experienced anti-HCV seroconversion
and developed chronic disease.
Two asymptomatic patients seroconverted and devel-
oped chronic disease without elevation of ALT or bilirubin
over the follow-up period (Fig. 1). So, these two patients
developed chronic HCV infection without any clinical or
laboratory evidence of hepatitis during the observation
period. The median time to seroconversion among 11
asymptomatic patients was 6 weeks (range: 3–18).
Two asymptomatic patients cleared the virus without
anti-HCV seroconversion and without ALT elevation
(Fig. 1). One of these patients cleared the virus by week
2 (genotype 1b) and another by week 4 (genotype 3a).
Both patients remained negative for plasma HCV RNA
and anti-HCV at the week 24 evaluation. Thus these two
cases can be described as transitory HCV viremia.
Analysis of HCV viral load dynamics showed that pa-
tients with transitory viremia had lower initial levels of
viral load – 3.68 log10 IU/ml in patient 1, who cleared
the virus by week 2, and 3.92 log10 IU/ml in patient 2
who cleared the virus by week 4 (Fig. 2). Among the
Table 1 Baseline characteristics of patients with recent HCV infection (n = 17)
Total Population (n = 17) Patients with spontaneous clearance (n = 4) Patients with chronic infections (n = 13)
Age, median years (range) 31 (22–39) 30 (22–31) 32 (24–39)
Sex, n (%)
Men 15 3 (20.0) 12 (80.0)
Women 2 1 (50.0) 1 (50.0)
Probable mode of HCV
transmission, n (%)
Injection drug use 12 2 (16.7) 10 (83.3)
Sexual contact 1 1 (100.0) 0 (0.0)
Undetermined 4 1 (25.0) 3 (75.0)
HCV genotype, n (%)
Genotype 1a 1 1 (100.0)
Genotype 1b 9 2 (22.2) 7 (77.8)
Genotype 2a/2c 3 1 (33.3) 2 (66.7)
Genotype 3a 4 1 (25.0) 3 (75.0)
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other two patients who cleared the virus, the initial viral
load was 4.27 log10 IU/ml in patient 3 and 4.14 log10 IU/
ml in patient 4 (Fig. 2). Patient 3 and 4 achieved peak
viral load at week 4 with 6.14 log10 IU/ml and 5.87 log10
IU/ml respectively (Fig. 2). Patients with persistent infec-
tion had a slower pace of increase in the viral load, with
peak median value registered at week 8–6.10 log10 IU/
ml (Fig. 3). A total of 9 patients with chronic infection
had viral load values of at least 6 log10 IU/ml over the
follow-up.
Discussion
We report the results of a unique study that followed
patients with recent HCV infection after the early days
of infection. We were able to identify these cases among
seronegative persons using qualitative PCR, which was
further confirmed by quantification of HCV RNA in
plasma. Our study described two very unusual trajector-
ies of acute HCV infection which may be more common
than have been appreciated in clinical studies.
The first is the case of transitory viremia, when 2
patients, positive for HCV RNA, spontaneously
cleared the virus without developing any clinical
symptoms, without ALT elevation and most surpris-
ingly without anti-HCV seroconversion. To the best
of our knowledge there have been only a few reports
of a similar abortive HCV infection [15–18]. In our
study, one patient remained viremic for up to 2 weeks
of follow-up, and another patient—for up to 4 weeks
of follow-up. The duration of viremia in all of the
above mentioned studies was short, and therefore
identification of these cases was possible only through
special design applied in studies. It is not surprising
that cases of transitory HCV viremia have not been
frequently identified since the majority of studies only
use recent anti-HCV seroconversion and ALT eleva-
tion as key criteria for defining acute HCV infection
[19]. Given the above mentioned difficulties related to
identification of transitory viremia, it remains un-
known how frequent transitory viremia and what are
Fig. 1 Clinical and laboratory variants of recent HCV infection (n = 17)
Fig. 2 HCV viral load dynamics among patients with spontaneous viral clearance (n = 4)
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its clinical and public health implications or whether
such patients have any immunity to subsequent HCV.
The other interesting form of acute HCV identified in
our study was the two asymptomatic patients with re-
cent infection who progressed to chronic hepatitis C
without elevation of ALT. Both patients experienced
seroconversion within the 24 weeks of follow-up. ALT
elevation, as an evidence of clinical hepatitis, occurs
shortly after the increase in the plasma HCV RNA levels
[3]. Although published data indicates that persistently
normal ALT during chronic HCV infection is not rare,
[20, 21] elevation of ALT is normally expected in estab-
lished infection regardless of the initial clinical presenta-
tion. Stramer and colleagues described three cases of
long-term HCV viremia for up to 3 year period without
elevated ALT, but these patients did not seroconvert
during the follow-up [15].
With regard to other clinical forms of disease, 4 patients
had symptomatic disease, including 3 patients who be-
came jaundiced, and two of them spontaneously cleared
the virus. Symptomatic disease, especially the occurrence
of jaundice, has been shown to be associated with higher
rates of spontaneous clearance of HCV [22, 23]. There
were 9 asymptomatic patients with elevated levels of ALT
and anti-HCV seroconversion, none of whom cleared the
virus. This is not entirely surprising, given that asymptom-
atic disease without elevated biochemical markers of
hepatitis has been associated with the lowest rate of spon-
taneous clearance, i.e about 10 % [23].
Overall the spontaneous viral clearance rate in our
study was 23.5 %, which is similar to the rate of 26 % es-
timated in a large systematic review [22]. Higher rates of
viral clearance of more than 40 % were reported more
recently from Brazil [24] and Egypt [25]. However, sub-
stantial proportion of the population of these cohorts
was symptomatic woman. Both symptomatic disease and
female sex have been associated with a more favorable
outcome of acute HCV infection, [22], including higher
clearance rates.
We found similar patterns of viral load dynamics of
the subjects in our study as other studies have re-
ported [3, 26–28]. Patients with spontaneous clear-
ance, excluding cases of transitory viremia, and those
with persistent infection had similar peak levels of
viral load, but the slope of increase in viral load early
in the course of infection was higher among patients
who cleared the infection. This result supports a re-
cent finding by Liu and colleagues [29] indicating an
association between high initial viral load and spon-
taneous clearance. However, we should be cautious
with this conclusion, since in our study there were
only four cases of viral clearance, of which two pa-
tients had transitory HCV viremia.
Our study identified another very important public
health challenge—the safety of blood and blood prod-
ucts when donors have only been screened serologic-
ally. The national program on blood safety in Georgia
was implemented in 1997 and currently ensures
screening of all donated blood for HIV, HBV, HCV
and syphilis. Implementation of this program resulted
in a significant reduction of transfusion transmitted
infections (TTI). However, as seen in our study the
program failed to detect 7 blood donors with recent
HCV due to the fact that the national program relies
only on antibody detection against this infection.
Since the late 1990s nucleic acid testing (NAT) of do-
nated blood become a gold standard in high income
countries, which minimized the residual risks of
transmission of viral agents [30]. Our study provides
evidence that justifies the introduction of NAT testing
of blood donors in Georgia. This is particularly im-
portant for HCV taking into consideration its high
prevalence in the country and longer seronegatve
window period than HIV [11].
Fig. 3 HCV viral load dynamics among patients with chronic infection (average value, n = 13)
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In addition to NAT testing donor selection remains a key
strategy for achieving the safety of the blood supply. The
majority of blood donors in Georgia are commercial do-
nors, who are at higher risk of HCV and other TTIs [13].
In our study, of 7 blood donors with recent HCV infection
2 were IDUs. During the study interview they disclosed a
recent history of sharing of injecting paraphernalia, but they
did not report this fact before donating blood. Efforts are
needed to increase voluntary donations and implement ef-
fective screening algorithm that accurately identifies blood
donors with high risk behaviors.
Our study has several limitations. First, a small number
of patients with recent HCV infection were identified,
which substantially limited the statistical power of the study
to assess associations and make meaningful comparisons.
The second possible limitation is the relatively short dur-
ation of follow-up. It is well established that the vast major-
ity of patients with spontaneous clearance after acute HCV
infection clear the virus within 6 months of infection, [3, 4]
subsequently we limited the follow-up in our study to
24 weeks. However, there are reports showing viral clear-
ance after 6 and even 12 months periods even in patients
with established chronic infection [31–33]. Thus it is pos-
sible that we missed some patients who might have cleared
the virus after the end of follow-up. Our study was not
powered to evaluate immunological aspects of recent HCV
infection, which might have provided explanations for rare
clinical cases seen in this study. Finally, it is now clear that
interleukin 28B (IL28B) plays an important role in spontan-
eous clearance of acute HCV, [34] but unfortunately stored
samples have not been available to test for IL28B
retrospectively.
Conclusions
In summary, our study identified and followed cases of
recent HCV infection after very early in their infection.
We described two of acute HCV, namely abortive HCV
infections without further seroconversion and a subject
with persistent infection without ALT elevation. Add-
itional studies are needed to define the clinical and pub-
lic health implications of transitory HCV viremia. Our
study emphasizes the urgent need for improving the
safety of the blood supply by implementing NAT testing
and promoting voluntary donations.
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